Cargando…

Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis

This meta-analysis has been conducted to compare ustekinumab and adalimumab as induction or maintenance therapy in patients with moderate to severe Crohn's disease (CD). The current meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Chenna, Venkata Sai Harshabhargav, Nagi, Talwinder K, Suarez, Zoilo K, Hernandez, Oscar L, Nageye, Maymona E, Reyaz, Nafisa, Reyaz, Ibrahim, Ali, Neelum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226155/
https://www.ncbi.nlm.nih.gov/pubmed/37255887
http://dx.doi.org/10.7759/cureus.38277
_version_ 1785050518082551808
author Chenna, Venkata Sai Harshabhargav
Nagi, Talwinder K
Suarez, Zoilo K
Hernandez, Oscar L
Nageye, Maymona E
Reyaz, Nafisa
Reyaz, Ibrahim
Ali, Neelum
author_facet Chenna, Venkata Sai Harshabhargav
Nagi, Talwinder K
Suarez, Zoilo K
Hernandez, Oscar L
Nageye, Maymona E
Reyaz, Nafisa
Reyaz, Ibrahim
Ali, Neelum
author_sort Chenna, Venkata Sai Harshabhargav
collection PubMed
description This meta-analysis has been conducted to compare ustekinumab and adalimumab as induction or maintenance therapy in patients with moderate to severe Crohn's disease (CD). The current meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Two investigators independently searched online databases including PubMed, Cumulated Index to Nursing and Allied Health Literature (CINAHL), and Cochrane Library for relevant articles published up to April 2023. The initial search terms were “ustekinumab,” “adalimumab,” and “Crohn’s disease". Three studies (with a total of 612 patients) were included in the present meta-analysis. We did not find any significant difference in clinical remission (OR: 1.31, 95% CI: 0.68-2.52), clinical response (OR: 1.39, 95% CI: 0.39-4.91), endoscopic remission (OR: 1.56, 95% CI: 0.66-3.64), and steroid-free remission (OR: 0.98, 95% CI: 0.67-1.42) between patients who received ustekinumab and patients who received adalimumab. In conclusion, this meta-analysis provides valuable insights into the efficacy and safety of ustekinumab and adalimumab in the treatment of moderate to severe CD. Our findings indicate that both drugs have similar effectiveness in achieving clinical remission, clinical response, radiological remission and steroid-free remission.
format Online
Article
Text
id pubmed-10226155
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-102261552023-05-30 Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis Chenna, Venkata Sai Harshabhargav Nagi, Talwinder K Suarez, Zoilo K Hernandez, Oscar L Nageye, Maymona E Reyaz, Nafisa Reyaz, Ibrahim Ali, Neelum Cureus Family/General Practice This meta-analysis has been conducted to compare ustekinumab and adalimumab as induction or maintenance therapy in patients with moderate to severe Crohn's disease (CD). The current meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Two investigators independently searched online databases including PubMed, Cumulated Index to Nursing and Allied Health Literature (CINAHL), and Cochrane Library for relevant articles published up to April 2023. The initial search terms were “ustekinumab,” “adalimumab,” and “Crohn’s disease". Three studies (with a total of 612 patients) were included in the present meta-analysis. We did not find any significant difference in clinical remission (OR: 1.31, 95% CI: 0.68-2.52), clinical response (OR: 1.39, 95% CI: 0.39-4.91), endoscopic remission (OR: 1.56, 95% CI: 0.66-3.64), and steroid-free remission (OR: 0.98, 95% CI: 0.67-1.42) between patients who received ustekinumab and patients who received adalimumab. In conclusion, this meta-analysis provides valuable insights into the efficacy and safety of ustekinumab and adalimumab in the treatment of moderate to severe CD. Our findings indicate that both drugs have similar effectiveness in achieving clinical remission, clinical response, radiological remission and steroid-free remission. Cureus 2023-04-29 /pmc/articles/PMC10226155/ /pubmed/37255887 http://dx.doi.org/10.7759/cureus.38277 Text en Copyright © 2023, Chenna et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Family/General Practice
Chenna, Venkata Sai Harshabhargav
Nagi, Talwinder K
Suarez, Zoilo K
Hernandez, Oscar L
Nageye, Maymona E
Reyaz, Nafisa
Reyaz, Ibrahim
Ali, Neelum
Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis
title Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis
title_full Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis
title_fullStr Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis
title_full_unstemmed Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis
title_short Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis
title_sort comparison of effectiveness and safety of ustekinumab and adalimumab as induction or maintenance therapy in patients with moderate to severe crohn's disease: a systematic review and meta-analysis
topic Family/General Practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226155/
https://www.ncbi.nlm.nih.gov/pubmed/37255887
http://dx.doi.org/10.7759/cureus.38277
work_keys_str_mv AT chennavenkatasaiharshabhargav comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis
AT nagitalwinderk comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis
AT suarezzoilok comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis
AT hernandezoscarl comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis
AT nageyemaymonae comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis
AT reyaznafisa comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis
AT reyazibrahim comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis
AT alineelum comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis